Evidence map›Paper›PMID 42084692›Full record

ArticleCurrent protocols2026

Affordable CRISPR RNP-Based Genome Editing in Euglena gracilis.

Anzu Minami, Minami Shimizu, Shun Tamaki, Vicki Nishinarizki, Yosua, Keiichi Mochida

Abstract read
In one paragraph

Article in Current protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anzu MinamiCenter for Sustainable Resource Science, RIKEN, Yokohama, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-8620-2695
Minami ShimizuCenter for Sustainable Resource Science, RIKEN, Yokohama, Kanagawa, Japan.
Shun TamakiDepartment of Biological Science, Faculty of Sciences and Engineering, Yasuda Women's University, Asaminami-ku, Hiroshima, Japan.ORCID https://orcid.org/0000-0001-8757-7512
Vicki NishinarizkiCenter for Sustainable Resource Science, RIKEN, Yokohama, Kanagawa, Japan.
YosuaCenter for Sustainable Resource Science, RIKEN, Yokohama, Kanagawa, Japan.
Keiichi MochidaCenter for Sustainable Resource Science, RIKEN, Yokohama, Kanagawa, Japan.ORCID https://orcid.org/0000-0003-1299-0024

Funding

This work was supported by the Japan Science and Technology Agency (JST) and the Japan International Cooperation Agency (JICA) through the Science and Technology Research Partnership for Sustainable Development (SATREPS) Program JPMJSA2204
6 · The paper itself

Abstract

Genome editing can enhance basic research and enable industrial applications of green algae. Here, we present an affordable, broadly applicable workflow for genome editing in the unicellular green alga Euglena gracilis using Cas9 nucleases. This method retains high editing efficiency while significantly lowering technical barriers. Unlike previous approaches that required specialized equipment, this protocol can be performed using a general-purpose laboratory electroporator and a simplified clonal isolation procedure without the need for specialized micromanipulation devices. This protocol is compatible with a range of editing outcomes, such as targeted deletions and precise base substitutions, enabling more widespread genome editing in Euglena. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Culture of Euglena gracilis Basic Protocol 2: sgRNA synthesis Basic protocol 3: Transformation Basic protocol 4: Genotyping.

Indexed as

CRISPR-Cas SystemsEuglena gracilisGene EditingRibonucleoproteinsRNA, Guide, CRISPR-Cas SystemsRibonucleoproteinsRNA, Guide, CRISPR-Cas SystemsCas9 nucleasesCRISPR ribonucleoprotein (RNP)‐based genome editingEuglena gracilistransformation

Identifiers

PMID42084692
PMCPMC13142649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.